---
schema_version: "secwatch.filing_event.v1"
accession: "0001851734-22-000422"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2022-08-10T23:59:59+00:00"
generated_at: "2026-06-24T01:22:11.404605+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ChromaDex Q2 net sales $16.7M (-5% YoY); CFO Farr terminated, Gerber interim CFO

## Summary
- Net sales $16.7M, down 5% YoY; Tru Niagen sales $14.5M (-6%). Gross margin 60%. Net loss $6.4M ($0.09 loss per share).
- CFO Kevin Farr terminated without cause on Aug 10, eff. Aug 12; Brianna Gerber appointed SVP Finance/Interim CFO.
- Hamed Shahbazi (CEO of WELL Health) appointed to Board, eff. Aug 9, joins Nominating and Corp Gov committee.
- Farr receives separation: 89,189 RSUs, $30,442 lump sum, accelerated equity vesting, pro-rata bonus, 90-day consulting.
- Company plans to reduce brand campaigns in H2 2022, shift focus to e-commerce and expense management.

## SEC filing metadata
- accession: 0001851734-22-000422
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2022-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000185173422000422/0001851734-22-000422-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000185173422000422/cdxc20220809_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001851734-22-000422
- JSON: https://secwatch.observer/filing/0001851734-22-000422.json
- Plain text: https://secwatch.observer/filing/0001851734-22-000422.txt

## Key facts
- Executive change
  Hamed Shahbazi was appointed as Director at Niagen Bioscience, Inc..
  - Action: appointed
  - Role: Director
  source text: On August 8, 2022, the Board appointed Hamed Shahbazi as a member of the Board effective as of August 9, 2022, to serve until the Company’s 2023 annual meeting of stockholders and until his successor is duly elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1386570/000185173422000422/0001851734-22-000422-index.htm
- Executive change
  Brianna Gerber was appointed as SVP, Finance / Interim Chief Financial Officer at Niagen Bioscience, Inc..
  - Action: appointed
  - Role: SVP, Finance / Interim Chief Financial Officer
  source text: On August 10, 2022, the Board of Directors of ChromaDex (the “Board”) appointed Brianna Gerber as SVP, Finance / Interim Chief Financial Officer, effective as of August 11, 2022, to replace the vacancy created by Mr. Farr’s termination as disclosed in item (a) above.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1386570/000185173422000422/0001851734-22-000422-index.htm
- Executive change
  Kevin Farr departed as Chief Financial Officer at Niagen Bioscience, Inc..
  - Action: terminated without cause
  - Role: Chief Financial Officer
  source text: On August 10, 2022, Kevin Farr was terminated without cause as Chief Financial Officer of the Company, and as an officer, employee, and director of the Company and any subsidiaries of the Company in which he serves in any of those capacities, effective as of August 12, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1386570/000185173422000422/0001851734-22-000422-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.